Trial Profile

Linagliptin, a novel DPP-4 inhibitor: no need for dose adjustment in patients with renal impairment.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Sep 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linagliptin (Primary)
Indications Type 2 diabetes mellitus
Focus Pharmacokinetics
Sponsors Boehringer Ingelheim

Most Recent Events

22 Sep 2010 New trial record
20 Sep 2010 Results reported at the 46th annual meeting of the European Association for the Study of Diabetes

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com